Idelalisib activates AKT via increased recruitment of PI3Kd/PI3Kß to BCR signalosome while reducing PDK1 in post-therapy CLL cells.
Idelalisib activates AKT via increased recruitment of PI3Kd/PI3Kß to BCR signalosome while reducing PDK1 in post-therapy CLL cells. Leukemia. 2022 07; 36(7):1806-1817.